Literature DB >> 25351484

Comparative survival of commercial probiotic formulations: tests in biorelevant gastric fluids and real-time measurements using microcalorimetry.

M Fredua-Agyeman1, S Gaisford1.   

Abstract

The large number of probiotic products now available makes the decision about which product to choose difficult both for the consumer and for the specialist providing dietary/nutritional advice. Data on the viability of the bacteria in these products, in an in vivo situation, are therefore important. This study was designed to explore the comparative health and survival of probiotic species in various commercial formulations, using more realistic test systems. This might allow further understanding of factors that must be controlled to optimise the delivery of live healthy bacteria to the lower gut. A total of eight commercially available probiotic preparations were selected for enumeration tests and in vitro gastric tolerance tests. Tolerance assays were conducted in porcine gastric fluid (PGF) fed and fasted state (pH 3.4±0.04), simulated gastric fluid (SGF, pH adjusted to 1.2 and 3.4) and fasted state simulated gastric fluid (FaSSGF, pH adjusted to 1.6 and 3.4). Isothermal microcalorimetry was also used to measure real-time growth of probiotics after exposure to simulated gastric fluid. Results from the enumeration tests indicated that recovery of viable organisms per dose is the same as or better than the stated label claims for liquid-based formulations, but lower than the stated claim for freeze-dried products. Results from the in vitro tolerance tests overall suggest that the PGF provided a harsher environment than the simulated systems at similar pH. In general, liquid-based products tested tended to give superior results in terms of survival compared with the freeze-dried products tested. Results from tests in the fed state in PGF suggested that food greatly affects viability. Microcalorimetric data showed that for some products probiotic species were able to grow following exposure to gastric fluid, suggesting that viable bacteria reach the gut in vivo.

Entities:  

Keywords:  Lactobacillus; gastric fluid; gastric tolerance; survival; viability

Mesh:

Year:  2015        PMID: 25351484     DOI: 10.3920/BM2014.0051

Source DB:  PubMed          Journal:  Benef Microbes        ISSN: 1876-2883            Impact factor:   4.205


  8 in total

1.  Compositional Quality and Potential Gastrointestinal Behavior of Probiotic Products Commercialized in Italy.

Authors:  Alessandra Vecchione; Francesco Celandroni; Diletta Mazzantini; Sonia Senesi; Antonella Lupetti; Emilia Ghelardi
Journal:  Front Med (Lausanne)       Date:  2018-03-07

Review 2.  Microbial Medicine: Prebiotic and Probiotic Functional Foods to Target Obesity and Metabolic Syndrome.

Authors:  Miranda Green; Karan Arora; Satya Prakash
Journal:  Int J Mol Sci       Date:  2020-04-21       Impact factor: 5.923

3.  The microbiota regulates murine inflammatory responses to toxin-induced CNS demyelination but has minimal impact on remyelination.

Authors:  Christopher E McMurran; Alerie Guzman de la Fuente; Rosana Penalva; Ofra Ben Menachem-Zidon; Yvonne Dombrowski; John Falconer; Ginez A Gonzalez; Chao Zhao; Fynn N Krause; Adam M H Young; Julian L Griffin; Clare A Jones; Claire Hollins; Markus M Heimesaat; Denise C Fitzgerald; Robin J M Franklin
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-18       Impact factor: 11.205

4.  Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease.

Authors:  Jonas Ghyselinck; Lynn Verstrepen; Frédéric Moens; Pieter Van Den Abbeele; Arnout Bruggeman; Jawal Said; Barry Smith; Lynne Ann Barker; Caroline Jordan; Valentina Leta; K Ray Chaudhuri; Abdul W Basit; Simon Gaisford
Journal:  Int J Pharm X       Date:  2021-07-02

Review 5.  Assessing Viability and Stress Tolerance of Probiotics-A Review.

Authors:  Ulrika Wendel
Journal:  Front Microbiol       Date:  2022-01-27       Impact factor: 5.640

6.  A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease.

Authors:  Ingvar Bjarnason; Guy Sission; Bu'Hussaine Hayee
Journal:  Inflammopharmacology       Date:  2019-05-03       Impact factor: 4.473

7.  How to Assess in vitro Probiotic Viability and the Correct Use of Neutralizing Agents.

Authors:  Luca Grispoldi; Riccardo Giglietti; Giovanna Traina; Beniamino Cenci-Goga
Journal:  Front Microbiol       Date:  2020-03-03       Impact factor: 5.640

Review 8.  Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention.

Authors:  Charlotte Skinner; Alex J Thompson; Mark R Thursz; Julian R Marchesi; Nikhil Vergis
Journal:  Therap Adv Gastroenterol       Date:  2020-10-16       Impact factor: 4.409

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.